At the recent SEC meeting for endocrinology and metabolism, the expert panel reviewed the proposal along with the ...

A new study published in the European Journal of Medical Research revealed that dapagliflozin, a sodium-glucose ...

The study tested the effects of balcinrenone/dapagliflozin, a drug combination, both in fed and fasted states, and with the addition of quinidine, a P-gp inhibitor. The purpose is to understand how ...

The SGLT2 inhibitor dapagliflozin was associated with a reduced risk for hospitalization due to any cause in patients with chronic kidney disease with and without type 2 diabetes, according to a ...

Dapagliflozin is a novel, selective, sodium glucose co-transporter 2 (SGLT2) inhibitor, currently being evaluated in Phase 3 trials as a once-daily oral therapy for the treatment of type 2 diabetes.

Dapagliflozin Benefits Low-EF Heart Failure Regardless of Diuretic Dose: DAPA-HF Steve Stiles June 10, 2020 0 ...

June 29, 2011 (San Diego, California) — Dapagliflozin in combination with metformin was found to increase blood glucose lowering compared with either agent alone in patients with newly diagnosed ...

PHILADELPHIA, PA—Dapagliflozin added to optimal medical therapy results in meaningful improvements in symptoms and health-related quality of life in heart failure patients with reduced ejection ...

Dapagliflozin was well tolerated among patients with an eGFR of less than 60 mL/minute per 1.73² and among those with an eGFR of greater than or equal to 60 mL/minute per 1.73².

Dapagliflozin, an investigational compound, is a potential first-in-class sodium-glucose cotransporter-2 (SGLT2) inhibitor currently in Phase 3 trials under joint development by Bristol-Myers ...